Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Gesto DS, Cerqueira NMFSA, Fernandes PA, Ramos MJ (2012) Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem 19:1076–1087

Article  CAS  PubMed  Google Scholar 

Galmarini C, Mackey J, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875–890

Article  CAS  PubMed  Google Scholar 

Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol 78:1–12

Article  CAS  PubMed  PubMed Central  Google Scholar 

Candelaria M, De la Cruz-Hernández E, Perez-Cardenas E, Trejo-Becerril C, Gutierrez-Hernandez O, Duenas-Gonzalez A (2010) Pharmacogenetics and pharmacoepigenetics of gemcitabine. Med Oncol 27:1133–1143

Article  CAS  PubMed  Google Scholar 

Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17:7–12

Article  Google Scholar 

Miao H, Chen X, Luan Y (2020) Small molecular gemcitabine prodrugs for cancer therapy. Curr Med Chem 27:5562–5582

Article  CAS  PubMed  Google Scholar 

Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J (2019) Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response? Br J Clin Pharmacol 85:1213–1214

Article  PubMed  PubMed Central  Google Scholar 

Giovannetti E, Laan A, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S et al (2008) Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27:720–725

Article  CAS  PubMed  Google Scholar 

Li J, Xu D, Huang J, Wang Y-N, Ma X-P, Lin Z-Y et al (2019) Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. Int J Biol Markers 34:389–397

Article  CAS  PubMed  Google Scholar 

Serdjebi C, Milano G, Ciccolini J (2015) Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin Drug Metab Toxicol 11:665–672

Article  CAS  PubMed  Google Scholar 

Ding X, Chen W, Fan H, Zhu B (2015) Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 559:31–37

Article  CAS  PubMed  Google Scholar 

Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V et al (2005) Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93:35–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A et al (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 28:160–165

Article  CAS  PubMed  Google Scholar 

Ciccolini J, Serdjebi C, Le Thi ThuH, Lacarelle B, Milano G, Fanciullino R (2016) Nucleoside analogs: ready to enter the era of precision medicine? Expert Opin Drug Metab Toxicol 12:865–877

Article  CAS  PubMed  Google Scholar 

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E et al (2015) FFCD-1004 clinical trial: impact of cytidine deaminase activity on clinical outcome in gemcitabine-monotherapy treated patients. PLoS ONE 10:1–12

Article  Google Scholar 

Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D’incecco A, Loosekoot N, et al (2012) Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 23:670–677

Article  CAS  PubMed  Google Scholar 

Cohen R, Preta L, Joste V, Curis E, Huillard O, Jouinot A et al (2019) Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. Br J Clin Pharmacol 85:1227–1238

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miri R, Saadati H, Ardi P, Firuzi O (2012) Alterations in oxidative stress biomarkers associated with mild hyperlipidemia and smoking. Food Chem Toxicol 50:920–926

Article  CAS  PubMed  Google Scholar 

Okamura T, Kigasawa K, Takeuchi T, Ohta C (1993) Cytidine deaminase activity in abnormal pregnancy. Int J Gynaecol Obstet 41:53–60

Article  CAS  PubMed  Google Scholar 

Peters GJ, Honeywell RJ, Maulandi M, Giovannetti E, Losekoot N, Etienne-Grimaldi M-C et al (2014) Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids 33:403–412

Article  CAS  PubMed  Google Scholar 

Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of gemcitabine in cancer therapy. Future Oncol 1:7–17

Article  CAS  PubMed  Google Scholar 

Rizzuto I, Ghazaly E, Peters GJ (2017) Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate. Pharmacogenomics 18:911–925

Article  CAS  PubMed  Google Scholar 

Hryciuk B, Szymanowski B, Romanowska A, Salt E, Wasąg B, Grala B et al (2018) Severe acute toxicity following gemcitabine administration: a report of four cases with cytidine deaminase polymorphisms evaluation. Oncol Lett 15:1912–1916

PubMed  Google Scholar 

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I et al (2018) Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. Br J Cancer 119:1326–1331

Article  CAS  PubMed  PubMed Central  Google Scholar 

Serdjebi C, Seitz JF, Ciccolini J, Duluc M, Norguet E, Fina F et al (2013) Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 14:1047–1051

Article  CAS  PubMed  Google Scholar 

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797–1803

Article  CAS  PubMed  Google Scholar 

Fanciullino R, Farnault L, Donnette M, Imbs D-C, Roche C, Venton G et al (2018) CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Adv 2:462–469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A et al (2013) Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapygender, cytidine deaminase, and 5-Aza/Decitabine. Clin Cancer Res 19:938–948

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buhagiar-Labarchède G, Onclercq-Delic R, Vacher S, Berger F, Bièche I, Stoppa-Lyonnet D et al (2022) Cytidine deaminase activity increases in the blood of breast cancer patients. Sci Rep 12:1–9

Google Scholar 

Carpi FM, Vincenzetti S, Ubaldi J, Pucciarelli S, Polzonetti V, Micozzi D et al (2013) CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population. Pharmacogenomics 14:769–781

Article  CAS  PubMed  Google Scholar 

Bhaskar L, Saikrishna L (2019) Molecular markers for treatment response and toxicity of gemcitabine. Breaking tolerance to pancreatic cancer unresponsiveness to chemotherapy. Elsevier, pp 175–195

Book  Google Scholar 

Ciccolini J, Mercier C, Dahan L, André N (2011) Integrating pharmacogenetics into gemcitabine dosing—time for a change? Nat Rev Clin Oncol 8:439–444

Article  CAS  PubMed  Google Scholar